Clinical observations suggest the combination may produce enhanced metabolic effects through complementary pathway activation, though formal human trials combining these specific agents remain limited as of 2026
Reduction of Abdominal and Visceral Fat : Animal and early human models have demonstrated a preferential reduction of abdominal fat following subcutaneous administration of AOD-9604
Inflammopharmacology 25 (4), 439449
And some products on the market test far below 85% purity
Administration Frequency: Due to its long half-life of 20 to 30 hours, it is typically administered once daily or 5 days per week (for EXAMPLE: excluding rest days)
Clinical Benefits Directly promotes healing of gastric and duodenal ulcers, reduces inflammatory bowel symptoms, protects against digestive tract damage, and enhances overall mucosal integrity